Glycogen storage disease type II: Difference between revisions
Jump to navigation
Jump to search
Irfan Dotani (talk | contribs) No edit summary |
Irfan Dotani (talk | contribs) No edit summary |
||
| Line 16: | Line 16: | ||
MeshID = D006009 | | MeshID = D006009 | | ||
}} | }} | ||
{{SK}} Glycogen storage disease type II; Pompe disease; acid maltase deficiency; glycogenosis type 2; alpha-1, 4-glucosidase deficiency | {{SK}} Glycogen storage disease type II; Pompe disease; acid maltase deficiency; glycogenosis type 2; alpha-1, 4-glucosidase deficiency | ||
Revision as of 19:50, 19 July 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
| Glycogen storage disease type II | |
| ICD-10 | E74.0 |
|---|---|
| ICD-9 | 271.0 |
| OMIM | 232300 |
| DiseasesDB | 5296 |
| MeSH | D006009 |
Synonyms and keywords: Glycogen storage disease type II; Pompe disease; acid maltase deficiency; glycogenosis type 2; alpha-1, 4-glucosidase deficiency
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Glycogen storage disease type I from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | X Ray | CT | MRI | Echocardiography or Ultrasound | Other Image Findings | Other Diagnostic Studies
Treatment
Medical Therapy | Surgery | Primary Prevention | Secondary Prevention | Cost-Effectiveness of Therapy | Future or Investigational Therapies